Literature DB >> 24799618

Radiation Dosimetry of (18)F-FPEB in Humans.

Robert M Kessler1, John Seibyl2, Ronald L Cowan3, David Zald4, Jacob S Young4, Mohammad Sib Ansari3, Michael G Stabin3.   

Abstract

UNLABELLED: (18)F-3-fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ((18)F-FPEB) is a potent and specific radioligand for the metabotropic glutamate receptor subtype 5 (mGluR5). Before undertaking clinical research studies with (18)F-FPEB, we performed studies of human radiation dosimetry.
METHODS: Serial whole-body scans were obtained in 9 healthy human subjects (5 men, 4 women) for 190-440 min after the intravenous administration of (18)F-FPEB. Radiation doses were estimated using the OLINDA/EXM software.
RESULTS: Peak organ doses were to the urinary bladder wall, 0.258 mGy/MBq (0.955 rad/mCi), and gallbladder wall, 0.193 mGy/MBq (0.716 rad/mCi). The effective dose was 0.025 mSv/MBq (0.0922 rem/mCi). The doses to the red marrow and spleen were 0.00797 mGy/MBq (0.0295 rad/mCi) and 0.00709 mGy/MBq (0.0262 rad/mCi), respectively. Reducing the urinary voiding interval to 60 or 90 min lowered the urinary bladder wall dose to 0.0885 mGy/MBq (0.327 rad/mCi) or 0.128 mGy/MBq (0.473 rad/mCi), respectively, and the effective dose to 0.0149 mSv/MBq (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectively.
CONCLUSION: Urinary voiding should be performed during (18)F-FPEB studies to minimize radiation exposure to research subjects.
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  18F-FPEB; glutamate; mGluR5; radiation dosimetry

Mesh:

Substances:

Year:  2014        PMID: 24799618     DOI: 10.2967/jnumed.113.133843

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

Review 1.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

2.  18F-Boramino acid PET/CT in healthy volunteers and glioma patients.

Authors:  Zhu Li; Ziren Kong; Junyi Chen; Jiyuan Li; Nan Li; Zhi Yang; Yu Wang; Zhibo Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-15       Impact factor: 9.236

Review 3.  Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.

Authors:  Rajapillai L I Pillai; Dnyanesh N Tipre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236

4.  Amyloid pathology induces dysfunction of systemic neurotransmission in aged APPswe/PS2 mice.

Authors:  Se Jong Oh; Namhun Lee; Kyung Rok Nam; Kyung Jun Kang; Sang Jin Han; Kyo Chul Lee; Yong Jin Lee; Jae Yong Choi
Journal:  Front Neurosci       Date:  2022-08-05       Impact factor: 5.152

5.  Pharmacokinetic Properties of 68Ga-labelled Folic Acid Conjugates: Improvement Using HEHE Tag.

Authors:  Anton Larenkov; Marat Rakhimov; Kristina Lunyova; Olga Klementyeva; Alesya Maruk; Aleksei Machulkin
Journal:  Molecules       Date:  2020-06-11       Impact factor: 4.411

6.  Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study.

Authors:  James Robert Brašić; Jack Alexander Goodman; Ayon Nandi; David S Russell; Danna Jennings; Olivier Barret; Samuel D Martin; Keith Slifer; Thomas Sedlak; Anil Kumar Mathur; John P Seibyl; Elizabeth M Berry-Kravis; Dean F Wong; Dejan B Budimirovic
Journal:  Brain Sci       Date:  2022-02-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.